MediSix Therapeutics, Inc.

BOSTON, MA · Founded 2019 · CIK 0001790058 · Biotech · Acquired

PEBL (Protein Expression BLocker), a technology to enhance CAR T-cell therapy efficacy for T-cell malignancies

medisixtx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$35M
2 Form D · Apr 2021
66 months since last filing
Contracts
—
No federal contracts on record
Patents
11
0 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$20,358,686
Private capital raisedForm D · SEC$15,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1170KODIAK BP, LLC—$13M
1171Nova Mentis Life Science Corp.—$188K
1172SCYNEXIS, INC.—$5.5M
1173MediSix Therapeutics, Inc.—$35M
1174ISOThrive Inc.—$17M
1175Unleash Immuno Oncolytics, Inc.—$3.0M
1176Cessation Therapeutics, Inc.—$6.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Andrew BruceDirector · Executive Officer
  • Michael CarusiDirector
  • William HarringtonDirector
  • Sarah LimExecutive Officer
  • Kenneth NoonanDirector · Executive Officer
  • George PosteDirector

Patents

USPTO · 0 granted of 11
  • Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
  • Blockade Of CD3 Expression And Chimeric Antigen Receptors For Immunotherapyapplication
  • Methods And Systems For Production Of Engineered T-cellsapplication
  • Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
  • Blockade Of CD3 Expression And Chimeric Antigen Receptors For Immunotherapyapplication
  • Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
  • Methods And Systems For Production Of Engineered T-cellsapplication
  • Blockade Of CD3 Expression And Chimeric Antigen Receptors For Immunotherapyapplication
  • Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
  • Engineered Immune Cells Expressing A Car And A Plurality Of Protein Expression Blockers And Uses Thereofapplication
  • Methods And Systems For Production Of Engineered T-cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.